TLDRs; Intel tested ACM’s wet tech tools despite the company’s China and Korea units being added to a US export blacklist. Unclear US export rules create major TLDRs; Intel tested ACM’s wet tech tools despite the company’s China and Korea units being added to a US export blacklist. Unclear US export rules create major

Intel Evaluates ACM Tools Despite Sanctions on China-Based Units

TLDRs;

  • Intel tested ACM’s wet tech tools despite the company’s China and Korea units being added to a US export blacklist.
  • Unclear US export rules create major uncertainty over whether ACM’s US arm can legally supply Intel’s advanced chip processes.
  • Policymakers warn Intel’s evaluation of tools linked to sanctioned affiliates may pose national security and technology transfer risks.
  • Potential restrictions could redirect market share to compliant wafer-cleaning equipment suppliers across the US, Japan, and Europe.

Intel Corporation is facing a new wave of scrutiny after evaluating semiconductor manufacturing tools from ACM Research, a California-based equipment firm whose Shanghai and South Korea subsidiaries were added to the U.S. Entity List in 2024.

According to individuals familiar with the matter, Intel tested ACM’s wet etch tools as part of its early preparations for the company’s next-generation 14A node, a process expected to enter production in 2027. While routine qualification of new equipment is common in chipmaking, this particular choice has triggered heightened attention from both regulators and industry analysts.

At the heart of the issue is whether ACM Research’s U.S. business can operate independently of its sanctioned foreign affiliates. The Commerce Department’s Entity List typically restricts not only the listed entities but also foreign companies in which they hold at least 50% ownership.

Testing Raises Regulatory Questions

The ambiguity surrounds more than just equipment purchases. Even if ACM’s U.S. arm is considered legally separate, analysts point out that modern semiconductor manufacturing tools often rely on global support networks.

Questions remain about whether software patches, maintenance services, or hardware components could indirectly involve ACM’s blacklisted units. If such interactions exist, supplying Intel could require export licenses that may not be granted, or may impose delays that are incompatible with Intel’s aggressive roadmap.

This regulatory uncertainty exposes Intel to procurement risks. Should BIS determine that the ACM-Intel interaction violates U.S. restrictions, Intel may be forced to replace the tools mid-development, raising the possibility of costly supply chain adjustments.

Sanctioned Affiliates Under Scrutiny

The U.S. government placed ACM’s Shanghai and Korean subsidiaries on the Entity List in December 2024 over allegations that they supported China’s military and advanced semiconductor development efforts. ACM has consistently denied the allegations, insisting that its operations comply with U.S. law.

Intel’s decision to evaluate tools associated with these subsidiaries has sparked national security concerns in Washington. Lawmakers argue that even limited cooperation with blacklisted-linked entities risks enabling sensitive technology transfer or undermining U.S. efforts to strengthen domestic chipmaking independence.

Intel has not said whether it plans to adopt the equipment for mass production, noting that tool testing does not automatically guarantee commercial use.

Supply Chain Risks Emerge

The uncertainty surrounding ACM’s eligibility could have broader consequences for Intel’s 14A timeline. If regulators block ACM from participating, Intel may have to pivot to alternative suppliers, potentially delaying early production milestones.

Moreover, the lack of clear BIS guidance on affiliated entities adds to the industry’s frustration over regulatory unpredictability at a time when U.S. chipmakers are already balancing geopolitical tensions, cost pressures, and rapid technological scaling.

Competitors Eye Market Openings

If ACM’s equipment becomes effectively unusable for U.S. chipmakers, the impact could reshape competition in the wafer-cleaning sector. Companies such as SCREEN Holdings, Tokyo Electron, and Lam Research, already leaders in wet-processing and single-wafer cleaning systems, stand poised to capture any displaced market share.

These firms are not affected by the current sanctions landscape and can offer compliant solutions that meet the particle-removal requirements of advanced EUV manufacturing.

Investors are also monitoring cryogenic CO₂ cleaning technologies, which continue to grow at a double-digit CAGR and could become viable alternatives for fabs seeking long-term, sanction-resistant equipment partners.

The post Intel Evaluates ACM Tools Despite Sanctions on China-Based Units appeared first on CoinCentral.

Market Opportunity
AC Milan Fan Token Logo
AC Milan Fan Token Price(ACM)
$0.5183
$0.5183$0.5183
-1.46%
USD
AC Milan Fan Token (ACM) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26